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Abstract: Injection into an experimentally injured spinal 
cord of a self-assembling peptide amphiphile (PA) that 
displays an IKVAV epitope reduced glial scarring and 
improved functional reclamation (Tysseling-Mattiace et 
al., 2008). Injection of a material that lacked this epitope 
did not alter outcome suggesting that signaling by the 
IKVAV epitope was central to the beneficial effects of 
IKVAV-PA. However the mechanical properties of 
implanted materials may also alter tissue and cell 
behavior in vivo (Discher et al., 2005). We therefore 
explored whether the mechanical properties of PAs might 
affect outcome after spinal cord injury. By treating 
animals with a spinal cord injury with different PAs that 
varied in their mechanical properties without epitope 
presentation, we found that the beneficial effects of the 
PAs are primarily dependent upon the presentation of a 
bioactive epitope presentation rather than the mechanical 
properties of the PA scaffold. 
Keywords: Self-assembling peptide amphiphile, 
functional recovery, spinal cord injury 
INTRODUCTION 
Spinal cord injury is a disease with no effective 
therapeutic intervention at the present time. 
Previously, our lab had reported that we were able 
to improve SCI functional reclamation by injecting 
self-assembling peptide amphiphile (PA) that 
displays an IKVAV epitope into the injured spinal 
cord (Tysseling-Mattiace et al., 2008). Injection of 
IKVAV-PA reduced glial scar formation, promoted 
corticospinal tract regeneration in the spinal cord, 
and enhanced behavioral outcome. The basic 
properties of peptide amphiphiles are described 
earlier in this paper. IKVAV (isoleucine-lysine-
valine-alanine-valine) is a natural sequence found 
in the laminin A chain which is thought to mediate 
the bioactivity of laminin (Tashiro et al., 1989, 
Agius et al., 1996).  
However there are studies suggesting that the 
mechanical properties of matrix material also 
contributing to their biological effects. As reviewed 
by Discher et al (2005), extracellular matrix 
stiffness is sensed through cell membrane 
anchorage proteins such as integrin, affecting cell 
proliferation, differentiation and migration. 
Specifically in the nervous system, studies on 
neurite growth have shown that the stiffness of 
hydrogels mediates their effects on the rate of 
neurite outgrowth (Man et al., 2011, Chen et al., 
2013). 
Ever since we found the beneficial effects of 
IKVAV PA for the treatment of spinal cord injury 
(Tysseling-Mattiace et al., 2008), we have been 
working with our collaborators to improve and 
optimize the PA based SCI treatment. An important 
issue within this effort was to understand the 
determinant factors of the effects of IKVAV PA.  
MATERIAL AND METHOD 
RAt spinal rope damage and PA infusion:  
Every creature method was performed as per the 
Public Health Service Policy on Humane Care and 
Use of Laboratory Animals and all techniques were 
endorsed by the Medical University Institutional 
Animal Care and Use Committee. Female Longs 
Evans Rats (two months of age) were anesthetized 
by the inward breath of 2.5% isoflurane soporific in 
100% oxygen managed by a VetEquip Rodent 
anesthesia machine. A T11 vertebral laminectomy 
was performed to uncover the spinal string. The 
spinal string was harmed utilizing an IH-0400 
Spinal Cord impactor (Precision Systems) with a 
1.25mm tip with a 2.50mm tip with 185 Kdynes of 
power and 60s of stay time. Skin was sutured 
utilizing AUTOCLIPs (9 mm; BD Biosciences). 
For postoperative care, creatures were continued a 
warming cushion for 24 h to keep up body 
temperature. After surgery, rats were given 
Buprenex (2.5mg/kg, s.c.) and Baytril (5 mg/kg, 
s.c.) to limit uneasiness and disease. Bladders were 
physically communicated twice day by day. A 5 
day Baytril treatment course (5 mg/kg day by day, 
s.c.) was begun in case of hematuria.  
Dad (1% watery arrangement) or vehicle was 
infused 48 h after SCI utilizing borosilicate glass 
narrow micropipettes (Sutter Instruments, Novato, 
CA) (external width, 100 μm). The vessels were 
stacked onto a Hamilton syringe utilizing a female 
luer connector (World Precision Instruments, 
Sarasota, FL) controlled by a Micro4 microsyringe 
pump controller (World Precision Instruments). 
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The amphiphile was weakened 1:1 with a 580 μM 
arrangement of glucose just before infusion and 
stacked into the slim. Under Avertin anesthesia, the 
autoclips were expelled and the damage site was 
uncovered. The micropipette was embedded to a 
profundity of 750μm measured from the dorsal 
surface of the string for mice and a profundity of 
1250 μm, and 5.0 μl of the weakened amphiphile 
arrangement or vehicle was infused at 1 μl/min. 
The micropipette was pulled back at interims of 
250 μm to leave a trail (ventral to dorsal) of the PA 
in the string. Toward the finish of the infusion, the 
slim tip was left in the line for an extra 1 min, after 
which the pipette was pulled back and the injury 
shut. For all analyses, the experimenters were kept 
blinded to the personality of the creatures. 
Statistical analyses: 
For comparison of behavioral BBB scoring 
between different injection groups, two-way 
ANOVA test was performed. 
RESULTS AND CONCLUS ION 
To investigate this possibility that the stiffness of 
PA supplied to the injury site influences outcome 
after spinal cord injury, we tested several PAs 
without bioactive epitopes that differed in their 
mechanical properties and compare them to a 
glucose vehicle. One of these PA (“linear PA”) has 
the same molecular backbone as IKVAV PA and 
should provide the same stiffness support as the 
IKVAV PA. The second PA has a similar 
molecular composition but a branched molecular 
structure design that increased the stiffness of the 
scaffold formed after gelation. 
We used our standardized impaction platform to 
injure adult rats. Two days after the injury, the 
severely injured rats (recognized as BBB score of 0 
on both hind limbs (Basso et al., 1996, Joshi and 
Fehlings, 2002b)) were injected with either control 
vehicle, linear PA or branched PA at their spinal 
cord injury site (week 0). Starting from the 
following week (week 1) to up to 3 months, the rats 
were assessed for their hind limb loco-mobility 
using standardized open field behavior scoring 
(BBB scoring) (Basso et al., 1996, Joshi and 
Fehlings, 2002b). During the scoring, the 
experimenters were blinded to the identity of the 
group to which the rats belonged (vehicle, linear 
PA or branched PA). After 12 weeks, we collected 
the BBB scores of each rat and quantitatively 
analyzed them. We found no functional 
improvement with either non-bioactive PA injected 
group compared with the vehicle control group, nor 
did we observe a difference between the two PA 
injected groups. This indicates that PA scaffolds 
capable of rendering stiffness support alone do not 
promote functional reclamation after spinal cord 
injury functional improvement in the absences of a 
bioactive epitope (such as IKVAV sequence). The 
findings also support the paper that IKVAV PA 
improves SCI recovery mainly through bioactive 
epitope (IKVAV) presentation. 
DISCUSSION AND CONCLUS IONS 
Advances in bioengineering and materials science 
have resulted in the creation of new materials that 
are promising candidates for therapeutic 
applications. Unlike conventional drugs which are 
typically soluble molecules, bioengineering 
materials that provide signals from an immobilized 
scaffold may benefit from their unique structural 
properties. In this paper we also demonstrated that 
two PAs with other bioactive epitopes (Tenascin C 
and RGD presenting PAs) exerted beneficial effects 
even larger than those of IKVAV-PA even though 
both of these PAs have the same stiffness structural 
support with IKVAV PA. This provides additional 
evidence that the bioactivity of the epitope is 
primarily responsible for the beneficial effects in 
spinal cord injury. 
However, the conclusion that the stiffness property 
of the PA scaffolds wasn’t the key factor for the 
therapeutic effects does not mean that the stiffness 
did not contribute. It is possible, and perhaps likely, 
that with a bioactive epitope attached the stiffness 
of scaffolds will contribute to the maximum 
presentation of the epitope. Thus modifying the 
stiffness of scaffold could possibly modify the 
accessibility of cells to contact and receive signal 
from the material, which ultimately could lead to a 
biological effect modification. This possibility can 
be addressed in future experiments that 
systematically examine changing the mechanical 
properties of epitope-presenting PAs.  
This paper were designed to help advance 
knowledge about the pathophysiology of spinal 
cord injury and to explore new therapeutic options. 
At present there are no therapeutic interventions 
that enhance regeneration after spinal cord injury, 
and the only current treatments are targeted at 
limiting secondary damages. 
There are multiple reasons for this. The first reason 
is the intrinsic vulnerability of central nervous 
tissue towards injury damage and the irreversibility 
of glial scar formation. The adult CNS has only 
limited regeneration capability. At the same time, 
the viability of neurons is critically dependent upon 
the delicate and integral microenvironment that the 
blood brain barrier helps to maintain. Once injuries 
have occurred and this balance is disrupted, 
sensitive neurons die, and a cascade of events is 
initiated that leads to a second wave of cell death in 
the early phases of spinal cord injury. Astrocytic 
hypertrophy helps to restore the blood brain barrier, 
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but a permanent glial scar is formed that acts as a 
physical barrier tor axonal regeneration. 
Another impediment is insufficient understanding 
of the detailed pathophysiologic processes 
underlying SCI, which limits the development of 
novel therapeutic inventions. One potential 
approach to modify this process is to limit glial scar 
formation which should reduce a major hurdle for 
axon regeneration. Accomplishing this will require 
understanding the nature of the precursor cells that 
contribute to the scar, the signaling mechanisms 
that mediate the process of scar formation, and the 
precise nature of the cells that form the scar. 
Without such knowledge it will be difficult to 
develop a targeted strategy for therapeutic 
invention. The nature of the cells in the scar has 
been reasonably well characterized. The 
predominant cell type in the scar is the astrocyte 
along with other cells including microglia, 
endothelial cells and fibroblasts. Astrocytes are the 
key component that limits axon regeneration. The 
cell bodies of astrocytes not only form tight 
junctions and physically block axon regeneration 
but they also secrete and/or bind molecules that 
inhibit axon outgrowth. One major group of these 
molecules is chondroitin sulfate proteoglycan 
(CSPGs). CSPGs inhibit axon regeneration through 
epidermal growth factor receptor (EGFR) mediated 
pathways (Koprivica et al., 2005). Blocking 
CSPGs’ inhibitory effect promotes axon 
regeneration after experimental spinal cord injury, 
achieving a therapeutic effect (Bradbury et al., 
2002, Bukhari et al., 2011). This demonstrates in 
principle that recovery form SCI can be improved 
by limiting the detrimental effects of the glial scar. 
Our group’s approach to limiting the detrimental 
effects of glial scar formation is not only to limit 
the presence of growth inhibiting molecules but 
also to reduce the overall astrocyte cell population 
in the glial scar. This should not only reduce the 
detrimental effects of inhibitory molecules bound 
to astrocytes but also should help to alleviate the 
physical obstruction to axon outgrowth. This 
attempt to reduce the astrocyte cell population in 
the glial scar is backed by our understanding of the 
astrocyte compositions within the scar. Astrogliosis 
and scar formation is comprised of two waves of 
events. 
The first phase could be summarized as local 
astrocyte hypertrophy. The injury induced toxic 
environment triggers local astrocyte reactive 
responses, with limited self-division and mainly 
cell body augmentation. This phase is considered 
beneficial for restoration of the blood brain barrier. 
The second and longer phase involves the influx of 
new astrocytes generated elsewhere that migrate 
into the injury site. These astrocytes add thickness 
to the scar tissue and stabilize it, but they are 
responsible for blocking axon regeneration. This 
recognition guides our attempt to mainly limit the 
second phase of astrocyte hyperplasia without 
limiting the initial hypertrophy. 
To design intervention strategies for new astrocyte 
generation, understanding the process of post injury 
astrocyte generation is essential. This includes 
identification of the progenitor cell population(s) 
which give rise to astrocytes plus the signaling 
mechanisms that control this process. It has been 
over a decade that the field recognized the presence 
of multipotent neural stem cells in adult spinal 
cord, which are ependymal cells that surround the 
central canal (Weiss et al., 1996, Johansson et al., 
1999). These cells have can give rise to 
neurospheres in vitro and are able to generate 
neurons, astrocytes and oligodendrocytes (Weiss et 
al., 1996, Johansson et al., 1999). Only recently 
was it recognized that the second wave of 
astrocytes generation following SCI actually came 
from ependymal cells (Meletis et al., 2008). Yet the 
signal mechanisms controlling astrocyte generation 
from ependymal cells are still largely unknown. 
This paper work has answered one piece of this 
question. 
Guided from a previous observation that IKVAV 
PA altered astrogliosis post spinal cord injury 
(Tysseling-Mattiace et al., 2008), we initiated an in 
vitro lineage commitment study of the effects of 
IKVAV PA on neural stem cells. We found that the 
neural stem cell membrane receptor β1 integrin 
plays a key role in regulating NSC differentiation 
into astrocytes. Through further experiments of 
targeted alteration of gene expression, including 
virus mediated gene knockout and bioengineering 
based gene signal augmentation, we confirmed that 
β1 integrin signaling inhibits astrocytic lineage 
commitment by NSCs. In addition, we did signal 
transduction exploration downstream of β1 integrin 
and found that astrocytic repression by β1 integrin 
is mediated, at least in part, by integrin linked 
kinase (ILK). We were able to rescue the astrocytic 
suppressive effects in β1 integrin null NSCs by 
inducing kinase activated ILK expression. 
Furthermore, we were also able to observe an 
astrocyte differentiation alteration by merely 
modifying ILK’s signal. 
This in vitro mechanistic work guided our attention 
back to in vivo pathophysiology in a spinal cord 
injury animal model. We found activation of β1 
integrin activation on NSCs in vivo in the IKVAV 
PA treated spinal cord, suggesting that the IKVAV 
PA reduced glial scar formation in vivo was 
achieved through activation of β1 integrin 
signaling. This suggests that targeted manipulation 
of β1 integrin signaling in acute stages of spinal 
cord injury might be a strategy for enhancing 
recovery. This is one very mechanistic hypothesis 
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that may guide and contribute to development of 
therapies for SCI therapy. Our hypothesis is 
supported by our recent finding that two additional 
PAs with epitopes known to activate β1 integrin 
(Tenascin C PA and RGDs PA) also showed 
beneficial effects in experimental SCI. 
The SCI therapeutic mechanism we proposed 
above would only effective for acute SCI, because 
it is targeted to modify the astrogliosis that takes 
place within the first two to three weeks of injury. 
In order to treat chronic SCI, a different therapeutic 
strategy had to be explored. At chronic stages of 
spinal cord injury, glial scar progression has 
reached a static state. In order to promote 
regeneration, one attempt has focused breaking the 
blockade of glial scar and rebuilding axon’s growth 
path. Different implantable nerve guidance 
channels have been extensively investigated 
(Straley et al., 2010, Joosten, 2012). In practice, the 
ideal nerve guidance channels should have 
following properties: non-toxic; degradable; 
resilient yet with sufficient mechanical strength for 
implantation; provide favorable environment for 
axons to grow, etc. Currently there is still no ideal 
material which can full fill all these criteria. What 
we report in this paper is a novel synthesized 
material with promising potential. 
We showed that we are able to build a semi-
automatic injection platform to inject a synthesized 
peptide solution into the spinal cord and create a 
nerve guidance channel capable of supporting 
neurite growth in vivo. This monodomain gel that 
we used is non-toxic, degradable, and mechanically 
strong enough to persist as an engraft. Moreover it 
also is able to provide bioactive signals through its 
epitope presenting capability and it guides neurite 
growth in a linear direction. This could potentially 
facilitate regrowth of fiber tracts such as the 
corticospinal tract. For a future research 
perspective, we plan to test this material’s 
capability to guide endogenous axon regeneration, 
which hasn’t been addressed in this paper. 
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